Scholarlink

<p>Methotrexate (MTX) is the anchor first-line drug for the treatment of rheumatoid arthritis (RA) in the RA guidelines of the ACR, JCR and EULAR. In the guidelines, MTX is primarily administered orally as low-dose pulse therapy. However, oral MTX therapy has a large interindividual variation of drug efficacy/adverse drug reactions due to bioavailability (BA) differences and it is often associated with gastrointestinal disturbances, making some patients unable to continue oral MTX therapy. MTX subcutaneous (SC) administration involves pain at the injection site and there are regulatory issues in disposal related to medical waste. The pyro-drive jet injector (PJI) is an innovative, needle-free drug delivery system that enables targeted delivery of drugs. This study investigated the pharmacokinetics (PK) and BA of MTX via the PJI in rats. PJI-injected India ink indicated penetration into the subcutis. The AUC<sub>0–∞</sub> after oral (PO) administration was significantly less than that after intravenous (IV), SC, and PJI administration. Absolute BA values with PO, SC, and PJI administration were 30.6%, 99.1%, and 100.8%, respectively. The relative BA of the PJI compared with the SC group was 101.7%. The administration of MTX using the PJI may be useful in clinical practice, but further studies, such as BA or bioequivalence tests, are necessary in animal species with skin similar to human skin or in humans.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A new, patient-friendly, needleless methotrexate administration method using the pyro-drive jet injector in rats

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月12日

查看全文
  • Mikiko Shimizu,
  • Tsuyoshi Shiga,
  • Masayuki Hashiguchi

摘要

Methotrexate (MTX) is the anchor first-line drug for the treatment of rheumatoid arthritis (RA) in the RA guidelines of the ACR, JCR and EULAR. In the guidelines, MTX is primarily administered orally as low-dose pulse therapy. However, oral MTX therapy has a large interindividual variation of drug efficacy/adverse drug reactions due to bioavailability (BA) differences and it is often associated with gastrointestinal disturbances, making some patients unable to continue oral MTX therapy. MTX subcutaneous (SC) administration involves pain at the injection site and there are regulatory issues in disposal related to medical waste. The pyro-drive jet injector (PJI) is an innovative, needle-free drug delivery system that enables targeted delivery of drugs. This study investigated the pharmacokinetics (PK) and BA of MTX via the PJI in rats. PJI-injected India ink indicated penetration into the subcutis. The AUC0–∞ after oral (PO) administration was significantly less than that after intravenous (IV), SC, and PJI administration. Absolute BA values with PO, SC, and PJI administration were 30.6%, 99.1%, and 100.8%, respectively. The relative BA of the PJI compared with the SC group was 101.7%. The administration of MTX using the PJI may be useful in clinical practice, but further studies, such as BA or bioequivalence tests, are necessary in animal species with skin similar to human skin or in humans.